公司资料
SeaStar Medical 股价、新闻与催化剂
- 股票代码:
- ICU
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
3.25 USD (+2.20%)
收盘价
最后更新: 2026年8月17日
14.1M USD
市值
股价为何变动
As of Aug 17, 2026, ICU closed up 2.20% at $3.25. No new same-company headline was identified in the current news window.
公司概览
Organ-Failure Immunomodulation Company
SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation.
Selective Cytopheretic Device
The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of inflammatory immune cells.
QUELIMMUNE
QUELIMMUNE is authorized for pediatric acute kidney injury and is being adopted by children’s hospitals under a Humanitarian Device Exemption.
Adult AKI Program
The pivotal NEUTRALIZE-AKI trial is evaluating the SCD in adults with acute kidney injury requiring continuous renal replacement therapy.
未来催化剂
- Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
- SeaStar plans to begin submitting PMA modules to the FDA as the adult AKI program progresses, with a potential full PMA filing in 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。